EHA 2015: Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression or death

ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma, met its primary endpoints of ... Author: EMJ Added: 06/13/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts